Allen Baharaff | President and Chief Executive Officer |
Yohai Stenzler | Chief Financial Officer |
Liat Hayardeny | Chief Scientific Officer |
Vlad Ratziu | Professor, Hepatology, Sorbonne Université |
Ryan Deschner | Raymond James |
Thomas Yip | H.C. Wainwright |
Justin Zelin | BTIG |
Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Third Quarter 2021. Today’s conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today’s call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today and actual results, trends, timelines and projections relating to our financial position and projected development programs and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our Annual Report on Form 20-F filed with the SEC and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today.